Ulinastatin and/or thymosin α1 for severe sepsis: A systematic review and meta-analysis

Journal of Trauma and Acute Care Surgery

Volumn 80, Issue 2, 2016, Pages 335-340

  Feng, Zhusheng ^a   Shi, Quanxing ^b   Fan, Yingnan ^a   Wang, Qianmei ^a   Yin, Wen ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b 306 HOSPITAL OF PLA   (China)

Author keywords

meta analysis; severe sepsis; systematic review; thymosin 1; Ulinastatin

Indexed keywords

ANTIBIOTIC AGENT; HYPERTENSIVE FACTOR; THYMOSIN ALPHA1; ULINASTATIN; GLYCOPROTEIN; IMMUNOLOGICAL ADJUVANT; THYMOSIN; TRYPSIN INHIBITOR;

APACHE; ARTIFICIAL VENTILATION; ASSESSMENT OF HUMANS; DRUG EFFICACY; GRADING OF RECOMMENDATIONS ASSESSMENT DEVELOPMENT AND EVALUATION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; META ANALYSIS; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY;

ADJUVANTS, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; GLYCOPROTEINS; HUMANS; SEPSIS; THYMOSIN; TRYPSIN INHIBITORS;

EID: 84957430576     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0000000000000909     Document Type: Review

References (35)

1. Li Y, Zhao T, Liu B, Halaweish I, Mazitschek R, Duan X, Alam HB,. Inhibition of histone deacetylase 6 improves long-term survival in a lethal septic model. J Trauma Acute Care Surg. 2015; 78 (2): 378-385.
2. Smith JW, Neal Garrison R, Matheson PJ, Harbrecht BG, Benns MV, Franklin GA, Miller KR, Bozeman MC, David Richardson J,. Adjunctive treatment of abdominal catastrophes and sepsis with direct peritoneal resuscitation: indications for use in acute care surgery. J Trauma Acute Care Surg. 2014; 77 (3): 393-398; 398-399.
3. Fry DE,. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am Surg. 2012; 78 (1): 1-8.
4. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013; 41 (2): 580-637.
5. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ,. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med. 2014; 42 (3): 625-631.
6. Nguyen HB, Smith D,. Sepsis in the 21st century: recent definitions and therapeutic advances. Am J Emerg Med. 2007; 25 (5): 564-571.
7. Lyle NH, Pena OM, Boyd JH, Hancock RE,. Barriers to the effective treatment of sepsis: antimicrobial agents, sepsis definitions, and host-directed therapies. Ann N Y Acad Sci. 2014; 1323: 101-114.
8. Chen CC, Wang SS, Lee FY,. Action of antiproteases on the inflammatory response in acute pancreatitis. JOP. 2007; 8 (Suppl 4): 488-494.
9. Li C, Bo L, Liu Q, Jin F,. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. Int J Infect Dis. 2015; 33: 90-96.
10. Kim BH, Lee YJ, Kim W, Yoon JH, Jung EU, Park SJ, Kim YJ, Lee HS,. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study. Scand J Gastroenterol. 2012; 47 (8-9): 1048-1055.
11. Maio M, Mackiewicz A, Testori A, Trefzer U, Ferraresi V, Jassem J, Garbe C, Lesimple T, Guillot B, Gascon P, Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol. 2010; 28 (10): 1780-1787.
12. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA,. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928.
13. Goldet G, Howick J,. Understanding GRADE: an introduction. J Evid Based Med. 2013; 6 (1): 50-54.
14. Huang SW, Chen J, Ouyang B, Yang CH, Chen MY, Guan XD,. Immunotherapy improves immune homeostasis and increases survival rate of septic patients. Chin J Traumatol. 2009; 12 (6): 344-349.
15. Li Y, Chen H, Li X, Zhou W, He M, Chiriva-Internati M, Wachtel MS, Frezza EE,. A new immunomodulatory therapy for severe sepsis: ulinastatin Plus Thymosin {alpha} 1. J Intensive Care Med. 2009; 24 (1): 47-53.
16. Cooperative Group of immunomodulatory Therapy of Sepsis, Lin HY,. Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin [in Chinese]. Zhonghua Yi Xue Za Zhi. 2007; 87 (7): 451-457.
17. Su L, Meng FS, Tang YQ, Wen Q, Liu YS, Tang LQ, Duan PK, Luo RJ,. Clinical effects of ulinastatin and thymosin alpha1 on immune-modulation in septic patients [in Chinese]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2009; 21 (3): 147-150.
18. Zhang Y, Chen H, Li YM, Zheng SS, Chen YG, Li LJ, Zhou L, Xie HY, Praseedom RK,. Thymosin alpha1-and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria. J Infect Dis. 2008; 198 (5): 723-730.
19. Karnad DR, Bhadade R, Verma PK, Moulick ND, Daga MK, Chafekar ND, Iyer S,. Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014; 40 (6): 830-838.
20. Wu TJ, Zhang LN, Kang CC,. The effect of ulinastatin on disbalance of inflammation and immune status in patients with severe sepsis [in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2013; 25 (4): 219-223.
21. Chen J,. Effects of thymosin-alpha1 on cell immunity function in patients with septic shock [in Chinese]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007; 19 (3): 153-155.
22. Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, Chen J, Ou-Yang B, Chen M, Li Y, The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013; 17 (1): R8.
23. Zhou LX, Tan JJ, Li YN, Luo HT, Shao YH, Qiang XH, Yu TO, Ma MY, Mao KJ, Fang B,. Immune and inflammation confusion in severe sepsis and effects of bi-immunomodulation therapy: a prospective, randomized, controlled clinical trial [in Chinese]. Zhonghua Yi Xue Za Zhi. 2009; 89 (15): 1028-1033.
24. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ,. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 101 (6): 1644-1655.
25. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004; 32 (3): 858-873.
26. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ,. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995; 23 (10): 1638-1652.
27. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344 (10): 699-709.
28. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G,. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31 (4): 1250-1256.
29. Antonopoulou A, Giamarellos-Bourboulis EJ,. Immunomodulation in sepsis: state of the art and future perspective. Immunotherapy. 2011; 3 (1): 117-128.
30. Goodwin AJ, Rice DA, Simpson KN, Ford DW,. Frequency, cost, and risk factors of readmissions among severe sepsis survivors. Crit Care Med. 2015; 43 (4): 738-746.
31. Li Y, Li J, Li N, Li Y, Wang J, Ni X, Li M,. Sixteen consecutive adult intestinal transplantation: a single-center clinical experience in China. Hepatogastroenterology. 2014; 61 (135): 1883-1888.
32. Bobb JF, Obermeyer Z, Wang Y, Dominici F,. Cause-specific risk of hospital admission related to extreme heat in older adults. JAMA. 2014; 312 (24): 2659-2667.
33. Boros M,. Microcirculatory analysis in the management of sepsis-Occam's razor or Achilles' heel? Crit Care Med. 2014; 42 (12): 2628-2630.
34. Lorigados CB, Ariga SK, Batista TR, Velasco IT, Soriano FG,. Endotoxaemic myocardial dysfunction: the role of coronary driving pressure in subendocardial perfusion. Crit Care Resusc. 2015; 17 (1): 12-22.
35. Opal SM, van der Poll T,. Endothelial barrier dysfunction in septic shock. J Intern Med. 2015; 277 (3): 277-293.